Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Positive Processes and Transition to Health (PATH)

NCT06093906 · View on ClinicalTrials.gov ↗

Study Summary

The R33 will be a randomized controlled trial to replicate changes in the targets (unproductive processing, avoidance, reward deficits) from the R61 phase in a larger sample of 135 participants who have experienced a destabilizing life event involving profound loss or threat, report persistent stressor-related symptoms of PTSD and/or depression, and are elevated on symptoms related to 2 of the 3 therapeutic targets. Additionally, this study will examine Positive Processes and Transition to Health (PATH)'s impact on stressor-related psychopathology in comparison to Progressive Muscle Relaxation (PMR). In the R33 phase, the investigators will examine changes in target mechanisms predicting improvements in PTSD and depressive symptoms, as well as feasibility and acceptability. Patients will receive 6 sessions of PATH or PMR (with 2 boosters, if partial responders). Primary targets will be assessed at pre-treatment, week 3, post-treatment, and at 1- and 3-month follow-up; secondary targets at pre-treatment, weekly during treatment, post-treatment, and at 1- and 3-month follow-ups.

Interventions

  • BEHAVIORAL Positive Processes and Transition to Health
  • BEHAVIORAL Progressive Muscle Relaxation

Study Locations (3)

Delaware

  • University of Delaware — Newark

Ohio

  • Case Western Reserve University — Cleveland

Washington

  • University of Washington — Seattle

Trial Details

FieldValue
Enrollment Target 135 participants
Start Date 2023-09-12
Est. Completion 2026-06-30
Phase NA

Sponsor

Case Western Reserve University

172 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06093906

The ClinicalTrials.gov registry entry for NCT06093906 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Western Reserve University, which has 172 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions — of which Positive Processes and Transition to Health is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06093906 reports 3 study locations spanning 3 distinct geographic areas — top geographies include Delaware, Ohio, Washington. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06093906 about?

NCT06093906 is a clinical study titled "Positive Processes and Transition to Health (PATH)". The R33 will be a randomized controlled trial to replicate changes in the targets (unproductive processing, avoidance, reward deficits) from the R61 phase in a larger sample of 135 participants who have experienced a destabilizing life event involving profound loss or threat, report persistent stres...

What is the current status of trial NCT06093906?

This trial is currently recruiting. It is a NA study. The enrollment target is 135 participants. The study started on 2023-09-12. Estimated completion is 2026-06-30.

What conditions does trial NCT06093906 study?

This clinical trial studies the following conditions: Major Depressive Disorder, Posttraumatic Stress Disorder. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06093906?

The interventions under investigation include: Positive Processes and Transition to Health (BEHAVIORAL), Progressive Muscle Relaxation (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06093906?

This trial is sponsored by Case Western Reserve University, which has 172 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06093906 being conducted?

This trial has 3 study locations across Delaware, Ohio, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial